Eslam Abu-Naeima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eslam Abu-Naeima has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Fayed
Nephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt
2 shared publications - Amin Roshdy Soliman
Cairo University, Egypt
2 shared publications - Mona A. Hegazy
Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications - Abdel Maguid Ramzy
Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt
1 shared publication - Ahmed Adel Elamragy
Cairo University, Giza, Egypt
1 shared publication Amany AbouZeid
Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 4 August 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 103
Non-hematological manifestations of vitamin B12 deficiency and excess: clinical spectrum and management
Background: Vitamin B12 deficiency is traditionally recognized through megaloblastic anemia, yet accumulating evidence shows a broad spectrum of non‑hematological manifestations and clinically relevant associations with elevated serum B12. Understanding these dimensions is essential for timely diagnosis and rational management across diverse populations. Objective: To synthesize current evidence on the non‑hematological clinical manifestations, diagnostic challenges, and management implications of Vitamin B12 deficiency and excess, with emphasis on high‑risk groups and emerging therapeutic approaches. Methods: A narrative review of human studies was conducted using PubMed, MEDLINE, Embase, Cochrane CENTRAL, Web of Science, Scopus, and Google Scholar from 1950 to 2024, supplemented by guideline documents and reference snowballing. Eligible publications examined non‑hematological outcomes or diagnostic and therapeutic aspects of vitamin B12 status; data were synthesized qualitatively with critical appraisal of study quality. Findings: Vitamin B12 deficiency is linked to neurological, cognitive, psychiatric, cardiovascular, reproductive, renal, dermatological, and oncologic manifestations that may occur in the absence of anemia. Functional deficiency often arises despite serum Vitamin B12 concentrations within the conventional reference range, making methylmalonic acid, homocysteine, and holotranscobalamin valuable adjunctive biomarkers, although interpretation is influenced by renal function and assay availability. High‑dose oral supplementation is generally non‑inferior to intramuscular therapy for correcting biochemical deficiency, while severe neuropsychiatric presentations and malabsorptive states frequently warrant parenteral regimens. Persistent hypervitaminemia B12 more commonly reflects underlying systemic disease—such as malignancy, liver or kidney dysfunction—than true toxicity, underscoring the need for etiological investigation rather than dose reduction alone. Elderly individuals, vegetarians/vegans, pregnant women, and post‑bariatric surgery patients constitute key risk groups requiring proactive screening and long‑term follow‑up. Conclusions: Vitamin B12 imbalance extends far beyond hematological abnormalities and should be considered in a wide range of neuropsychiatric, cardiometabolic, reproductive, and systemic presentations. Integrating functional biomarkers into diagnostic algorithms, individualizing replacement strategies, and prioritizing high‑risk populations may improve outcomes and align clinical practice with emerging evidence. Future research should focus on standardized diagnostic thresholds, long‑term neurocognitive and cardiovascular endpoints, and pharmacogenomic and novel delivery strategies to support precision supplementation.
- 4 August 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 103
Open AccessNon-hematological manifestations of vitamin B12 deficiency and excess: clinical spectrum and management
Background: Vitamin B12 deficiency is traditionally recognized through megaloblastic anemia, yet accumulating evidence shows a broad spectrum of non‑hematological manifestations and clinically relevant associations with elevated serum B12. Understanding these dimensions is essential for timely diagnosis and rational management across diverse populations. Objective: To synthesize current evidence on the non‑hematological clinical manifestations, diagnostic challenges, and management implications of Vitamin B12 deficiency and excess, with emphasis on high‑risk groups and emerging therapeutic approaches. Methods: A narrative review of human studies was conducted using PubMed, MEDLINE, Embase, Cochrane CENTRAL, Web of Science, Scopus, and Google Scholar from 1950 to 2024, supplemented by guideline documents and reference snowballing. Eligible publications examined non‑hematological outcomes or diagnostic and therapeutic aspects of vitamin B12 status; data were synthesized qualitatively with critical appraisal of study quality. Findings: Vitamin B12 deficiency is linked to neurological, cognitive, psychiatric, cardiovascular, reproductive, renal, dermatological, and oncologic manifestations that may occur in the absence of anemia. Functional deficiency often arises despite serum Vitamin B12 concentrations within the conventional reference range, making methylmalonic acid, homocysteine, and holotranscobalamin valuable adjunctive biomarkers, although interpretation is influenced by renal function and assay availability. High‑dose oral supplementation is generally non‑inferior to intramuscular therapy for correcting biochemical deficiency, while severe neuropsychiatric presentations and malabsorptive states frequently warrant parenteral regimens. Persistent hypervitaminemia B12 more commonly reflects underlying systemic disease—such as malignancy, liver or kidney dysfunction—than true toxicity, underscoring the need for etiological investigation rather than dose reduction alone. Elderly individuals, vegetarians/vegans, pregnant women, and post‑bariatric surgery patients constitute key risk groups requiring proactive screening and long‑term follow‑up. Conclusions: Vitamin B12 imbalance extends far beyond hematological abnormalities and should be considered in a wide range of neuropsychiatric, cardiometabolic, reproductive, and systemic presentations. Integrating functional biomarkers into diagnostic algorithms, individualizing replacement strategies, and prioritizing high‑risk populations may improve outcomes and align clinical practice with emerging evidence. Future research should focus on standardized diagnostic thresholds, long‑term neurocognitive and cardiovascular endpoints, and pharmacogenomic and novel delivery strategies to support precision supplementation.
- Open Access
- 10 July 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 87
Low dose aspirin beyond coronary artery disease: a structured narrative review
Background: During the past decades, several innovations in the antiplatelet field were established; including its role in the primary and secondary prevention of atherosclerotic cardiovascular diseases (ASCVD), the development of newer efficient and more safe antiplatelet drugs, moreover, evidence has also accrued on its therapeutic potential that may extend beyond cardiovascular applications, with implications for broader population health and nutrition strategies. This possible role of low-dose aspirin (LDA) has changed the future of aspirin use. Objectives: This structured narrative review explores the evolving role of LDA in the different fields of medicine beyond cardiovascular indications, including nephrology/vascular access, endocrinology/metabolic disorders, oncology, obstetrics, neurology, gastroenterology/hepatology, rheumatology, respiratory medicine, geriatrics/polypharmacy, and primary care/health systems. The review will also offer a clinical perspective on aspirin’s mechanism of action beyond the antiplatelet effects, anti-inflammatory pathways, and novel mechanisms. It aims to synthesize current evidence, assess the relevance of aspirin as a low-cost, scalable intervention within diverse populations and critically evaluate recent guideline changes regarding primary prevention. Methods: We searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus (inception to January 2025) for studies on LDA beyond cardiovascular disease to identify studies, reviews, and guidelines related to LDA use in non- coronary artery disease (non-CAD) populations. Emphasis was placed on epidemiological findings, clinical trials, and public health perspectives that intersect with nutritional status, chronic disease risk, and health equity. Results: Findings highlight the strong recommendations of LDA in reducing preeclampsia risk in high-risk pregnant women. For the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) mutated stage II-III colon cancer, LDA lowered recurrence risk by nearly 50%. High-risk antiphospholipid syndrome (APS) patients showed significant thrombosis reduction. Many other medical conditions need shared decision making; however, major bleeding risk increased 1.5–2.0-fold, with additional risk of intracranial hemorrhage, particularly in adults > 70 years. Conclusion: LDA holds a promise as a multifaceted agent in preventive health beyond CAD. Its potential applications warrant further investigation, particularly in high-risk groups.
- 10 July 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 87
Open AccessLow dose aspirin beyond coronary artery disease: a structured narrative review
Background: During the past decades, several innovations in the antiplatelet field were established; including its role in the primary and secondary prevention of atherosclerotic cardiovascular diseases (ASCVD), the development of newer efficient and more safe antiplatelet drugs, moreover, evidence has also accrued on its therapeutic potential that may extend beyond cardiovascular applications, with implications for broader population health and nutrition strategies. This possible role of low-dose aspirin (LDA) has changed the future of aspirin use. Objectives: This structured narrative review explores the evolving role of LDA in the different fields of medicine beyond cardiovascular indications, including nephrology/vascular access, endocrinology/metabolic disorders, oncology, obstetrics, neurology, gastroenterology/hepatology, rheumatology, respiratory medicine, geriatrics/polypharmacy, and primary care/health systems. The review will also offer a clinical perspective on aspirin’s mechanism of action beyond the antiplatelet effects, anti-inflammatory pathways, and novel mechanisms. It aims to synthesize current evidence, assess the relevance of aspirin as a low-cost, scalable intervention within diverse populations and critically evaluate recent guideline changes regarding primary prevention. Methods: We searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus (inception to January 2025) for studies on LDA beyond cardiovascular disease to identify studies, reviews, and guidelines related to LDA use in non- coronary artery disease (non-CAD) populations. Emphasis was placed on epidemiological findings, clinical trials, and public health perspectives that intersect with nutritional status, chronic disease risk, and health equity. Results: Findings highlight the strong recommendations of LDA in reducing preeclampsia risk in high-risk pregnant women. For the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) mutated stage II-III colon cancer, LDA lowered recurrence risk by nearly 50%. High-risk antiphospholipid syndrome (APS) patients showed significant thrombosis reduction. Many other medical conditions need shared decision making; however, major bleeding risk increased 1.5–2.0-fold, with additional risk of intracranial hemorrhage, particularly in adults > 70 years. Conclusion: LDA holds a promise as a multifaceted agent in preventive health beyond CAD. Its potential applications warrant further investigation, particularly in high-risk groups.
- Open Access
- 2 April 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 35
Triglyceride-glucose index (TyG) as a predictor of insulin resistance and peripheral artery disease in patients with type 2 diabetes mellitus
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic illness distinguished by insulin resistance (IR), impaired production of insulin, and elevated blood sugar concentration. Prevention focuses on healthy living & managing risks. Peripheral artery disease (PAD) shares risk factors with type 2 diabetes, but diabetes significantly contributes to its development & progression. Chronic high blood sugar and IR worsen microvascular & macrovascular complications, potentially leading to limb amputation. We aimed in this research to assess the serum triglyceride glucose index (TyG index) level as possible screening & severity biomarker of IR & in prediction of PAD. We further tried to correlate the level of this biomarker with different clinical features of the cases & other laboratory tests. Methods: This case-control study was conducted on 110 subjects, classified into two groups: 55 T2DM with no known PAD manifestations and 55 apparently healthy subjects as a control group recruited from the internal medicine, diabetes, and endocrinology outpatient clinics at Kasr Al Ainy Hospital, Cairo University, across a 20-month duration from October 2022 to March 2024. Data collection included the lipid profile, fasting insulin, fasting blood glucose (FBS), & glycated hemoglobin (HbA1c). Homeostatic model assessment of insulin resistance (HOMA IR) has been determined with regard to formula: HOMA-IR = {fasting glucose (milligram per decilitre) ×fasting insulin (international unit per millilitres)} /405. The TyG index has been determined as: ln (fasting triglycerides [milligram per decilitre] × fasting blood glucose [milligram per decilitre] /2). The ankle-brachial index (ABI) has been calculated utilizing a high-resolution color-coded Doppler Ultrasonography and the presence of PAD was described as right or left ABI ≤ 0.9. Statistical analyses focused on exploring the efficacy of TyG index for diagnosis of IR and PAD. Results: PAD is significantly greater among diabetic cases in comparison with control group (p value < 0.001). In diabetic cases, a significant positive association has been detected between triglyceride glucose index (TyG index) & (duration of diabetes, total cholesterol, Hb A1c, fasting insulin, and HOMA IR) with a significant negative association has been found among TyG index & ABI with p value < 0.001. ROC curve was done for TyG index for diagnosis of IR showed that a cut off value above nine had a sensitivity & specificity 98% and 93% respectively with area under the curve (AUC) 0.98 with p value < 0.001. ROC curve was done for TyG index + for diagnosis of PAD showed that a cut off value > 9.7 showed a higher sensitivity & specificity 89%and 90% respectively with AUC 0.9 with p value < 0.001. The logistic regression model showed that TyG index is the only indicator of PAD. Conclusion: We report a significant correlation among TyG index & both of IR & PAD. TyG index is an inexpensive, rapid marker that may be applied in the determination of IR& the prediction of PAD in type 2 diabetic cases.
- 2 April 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 35
Open AccessTriglyceride-glucose index (TyG) as a predictor of insulin resistance and peripheral artery disease in patients with type 2 diabetes mellitus
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic illness distinguished by insulin resistance (IR), impaired production of insulin, and elevated blood sugar concentration. Prevention focuses on healthy living & managing risks. Peripheral artery disease (PAD) shares risk factors with type 2 diabetes, but diabetes significantly contributes to its development & progression. Chronic high blood sugar and IR worsen microvascular & macrovascular complications, potentially leading to limb amputation. We aimed in this research to assess the serum triglyceride glucose index (TyG index) level as possible screening & severity biomarker of IR & in prediction of PAD. We further tried to correlate the level of this biomarker with different clinical features of the cases & other laboratory tests. Methods: This case-control study was conducted on 110 subjects, classified into two groups: 55 T2DM with no known PAD manifestations and 55 apparently healthy subjects as a control group recruited from the internal medicine, diabetes, and endocrinology outpatient clinics at Kasr Al Ainy Hospital, Cairo University, across a 20-month duration from October 2022 to March 2024. Data collection included the lipid profile, fasting insulin, fasting blood glucose (FBS), & glycated hemoglobin (HbA1c). Homeostatic model assessment of insulin resistance (HOMA IR) has been determined with regard to formula: HOMA-IR = {fasting glucose (milligram per decilitre) ×fasting insulin (international unit per millilitres)} /405. The TyG index has been determined as: ln (fasting triglycerides [milligram per decilitre] × fasting blood glucose [milligram per decilitre] /2). The ankle-brachial index (ABI) has been calculated utilizing a high-resolution color-coded Doppler Ultrasonography and the presence of PAD was described as right or left ABI ≤ 0.9. Statistical analyses focused on exploring the efficacy of TyG index for diagnosis of IR and PAD. Results: PAD is significantly greater among diabetic cases in comparison with control group (p value < 0.001). In diabetic cases, a significant positive association has been detected between triglyceride glucose index (TyG index) & (duration of diabetes, total cholesterol, Hb A1c, fasting insulin, and HOMA IR) with a significant negative association has been found among TyG index & ABI with p value < 0.001. ROC curve was done for TyG index for diagnosis of IR showed that a cut off value above nine had a sensitivity & specificity 98% and 93% respectively with area under the curve (AUC) 0.98 with p value < 0.001. ROC curve was done for TyG index + for diagnosis of PAD showed that a cut off value > 9.7 showed a higher sensitivity & specificity 89%and 90% respectively with AUC 0.9 with p value < 0.001. The logistic regression model showed that TyG index is the only indicator of PAD. Conclusion: We report a significant correlation among TyG index & both of IR & PAD. TyG index is an inexpensive, rapid marker that may be applied in the determination of IR& the prediction of PAD in type 2 diabetic cases.
- Open Access
- 27 March 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
Venous Excess Doppler ultrasound assessment and loop diuretic efficiency in acute cardiorenal syndrome
Background: Cardiorenal syndrome poses significant diagnostic and therapeutic challenges. The Venous Excess Ultrasound (VExUS) grading system based on the combination of venous Doppler assessments has shown potential in predicting acute kidney injury and cardiovascular outcomes, but its relevance regarding the management of acutely decompensated heart failure (ADHF) remains to be fully understood. Methods: In this prospective study, patients with ADHF and acute kidney injury (AKI) were enrolled from a medical intensive care unit over 20 months. The study involved echocardiography and VExUS grading at admission and 72 h later. Data collection included clinical parameters, diuretic dosages, urine output, and fluid balance. Statistical analyses focused on exploring the relationships between VExUS grades and its components, including the renal venous stasis index (RVSI), diuretic efficiency, and renal function improvement. Results: The cohort of 43 patients showed varied VExUS grades at admission. Higher VExUS grades were significantly associated with lower diuretic efficiency. Specifically, the mean urine output per 40 mg of furosemide was 368 ± 213 mL, with patients having VExUS grade 2 or 3 exhibiting reduced diuretic efficiency compared to those with grade 0–1 (Grade 2 vs. Grade 0–1: 333 ± 214 mL vs. 507 ± 189 mL, p = 0.02; Grade 3 vs. Grade 0–1: 270 ± 167 mL vs. 507 ± 189 mL, p = 0.004). The relationship between VExUS grade and diuretic efficiency was independent of admission creatinine and prior use of loop-diuretics (β = -106 CI: -180; -32 p = 0.006). Among the components of venous congestion assessment, the RVSI had the best ability to predict low diuretic efficiency (AUROC: 0.76 (0.60; 091) p = 0.001). Improvement in VExUS grade at 72 h was correlated with significant renal function improvement (84.6% vs. 47.1% for improved vs. non-improved VExUS grades, p = 0.03). Conclusion: High VExUS and RVSI grades at admission are independently associated with reduced diuretic efficiency in ADHF patients with AKI. The findings emphasize the clinical value of venous congestion assessment in cardiorenal syndrome management including the selection of an initial diuretic dose.
- 27 March 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
Open AccessVenous Excess Doppler ultrasound assessment and loop diuretic efficiency in acute cardiorenal syndrome
Background: Cardiorenal syndrome poses significant diagnostic and therapeutic challenges. The Venous Excess Ultrasound (VExUS) grading system based on the combination of venous Doppler assessments has shown potential in predicting acute kidney injury and cardiovascular outcomes, but its relevance regarding the management of acutely decompensated heart failure (ADHF) remains to be fully understood. Methods: In this prospective study, patients with ADHF and acute kidney injury (AKI) were enrolled from a medical intensive care unit over 20 months. The study involved echocardiography and VExUS grading at admission and 72 h later. Data collection included clinical parameters, diuretic dosages, urine output, and fluid balance. Statistical analyses focused on exploring the relationships between VExUS grades and its components, including the renal venous stasis index (RVSI), diuretic efficiency, and renal function improvement. Results: The cohort of 43 patients showed varied VExUS grades at admission. Higher VExUS grades were significantly associated with lower diuretic efficiency. Specifically, the mean urine output per 40 mg of furosemide was 368 ± 213 mL, with patients having VExUS grade 2 or 3 exhibiting reduced diuretic efficiency compared to those with grade 0–1 (Grade 2 vs. Grade 0–1: 333 ± 214 mL vs. 507 ± 189 mL, p = 0.02; Grade 3 vs. Grade 0–1: 270 ± 167 mL vs. 507 ± 189 mL, p = 0.004). The relationship between VExUS grade and diuretic efficiency was independent of admission creatinine and prior use of loop-diuretics (β = -106 CI: -180; -32 p = 0.006). Among the components of venous congestion assessment, the RVSI had the best ability to predict low diuretic efficiency (AUROC: 0.76 (0.60; 091) p = 0.001). Improvement in VExUS grade at 72 h was correlated with significant renal function improvement (84.6% vs. 47.1% for improved vs. non-improved VExUS grades, p = 0.03). Conclusion: High VExUS and RVSI grades at admission are independently associated with reduced diuretic efficiency in ADHF patients with AKI. The findings emphasize the clinical value of venous congestion assessment in cardiorenal syndrome management including the selection of an initial diuretic dose.